Trials / Terminated
TerminatedNCT00293111
Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)
An Open Label, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- Cephalon · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An Open Label, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-Etodolac) in Patients with Relapsed or Refractory Multiple Myeloma (MM)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SDX-101 (R-Etodolac) |
Timeline
- Start date
- 2002-02-01
- Primary completion
- 2003-10-01
- First posted
- 2006-02-17
- Last updated
- 2014-05-12
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00293111. Inclusion in this directory is not an endorsement.